Harnessing the power of prevention: Human papillomavirus vaccines

Current Opinion in Obstetrics and Gynecology

Volumn 18, Issue SUPPL. 1, 2006, Pages

  Mayeaux Jr , Edward J ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Cervical cancer; Genital warts; Human papillomavirus (HPV); Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA; DRUG SAFETY; HEALTH CARE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS STRAIN; VIRUS TRANSMISSION; WART VIRUS;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CONDYLOMATA ACUMINATA; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 33744739546     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000216316.10690.c6     Document Type: Review

References (52)

1. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92:464-474.
2. Cates WJ. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999; 26 (suppl 4):S2-S7.
3. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates. Perspect Sex Reprod Health 2004; 36:6-10.
4. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191:182-192.
5. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31:3-13.
6. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001; 11:598-603; quiz 604.
7. Brown DR, Bryan JT, Schroeder JM, et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 2001; 184:1183-1186.
8. Harper DM. Why am I scared of HPV? CA Cancer J Clin 2004; 54:245-247.
9. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10:122-163.
10. Armstrong LR, Preston EJ, Reichert M, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000; 31:107-109.
11. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31:14-19.
12. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
13. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
14. National Toxicology Program DHHS. The report on carcinogens. Washington DC: Federal Register 2005; 70.
15. IARC working group. IARC monographs on the evaluation ofcarcinogenic risks to humans: human papillomaviruses. Lyon, France: International Agency for Research on Cancer 1995; 64.
16. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23:2388-2394.
17. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000; 96:653-656.
18. Holcomb B, Bailey JM, Crawford K, Ruffin MT. Adults' knowledge and behaviors related to human papillomavirus infection. J Am Board Fam Pract 2004; 17:26-31.
19. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004; 191:114-120.
20. The Kaiser Family Foundation and the American Social Health Association. Sexually transmitted diseases in America: how many cases and at what cost? Menlo Park, CA: Kaiser Family Foundation; 1998.
21. Fisman DN, Lipsitch M, Hook EW, Goldie SJ. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex Transm Dis 2002; 29:608-622.
22. Eng TR, Butler WT, editors. Institute of Medicine: Division of Health Promotion and Disease Prevention. Hidden epidemic: confronting sexually transmitted diseases. Washington (DC): National Academy Press; 1997.
23. Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth. Perspect Sex Reprod Health 2004; 36:11-19.
24. Kulasingam SL, Harper DM, Meyers ER. Paper presented at: International HPV Conference. Paris, France, 2002.
25. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287:2372-2381.
26. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36:1397-1403.
27. Lowy DR, Frazer IH. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003; 111-116.
28. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185:251-257.
29. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993; 67:315-322.
30. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2:343-347.
31. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000; 92:397-402.
32. Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiplehuman papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37:3316-3322.
33. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995; 92:11553-11557.
34. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995; 13:1509-1514.
35. Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 2001; 279:361-369.
36. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95:1128-1137.
37. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93:284-292.
38. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
39. Ault KA, Giuliano AR, Edwards RP, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004; 22:3004-3007.
40. Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 2004; 22:2943-2952.
41. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-1765.
42. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
43. Herrero R, Schiffman MH, Bratti C, et al. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1997; 1:362-375.
44. Bratti MC, Rodriguez AC, Schiffman M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica 2004; 15:75-89.
45. Skjeldestad FE, FUTURE II steering committee. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Presented at: Infectious Disease Society of America, 2005. San Francisco, Calif.
46. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:37-48.
47. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13:631-639.
48. Taira AV. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10:1915-1923.
49. Baer H, Allen S, Braun L. Knowledge of human papillomavirus infection among young adult men and women: implications for health education and research. J Commun Health 2000; 25:67-78.
50. Wexler D editor. Needle tips and the hepatitis B coalition news. St Paul, MN: The Immunization Action Coalition; 2004.
51. Sexually transmitted infections quarterly report: anogenital warts and HSV infection in England and Wales. Communicable Dis Rep 2001; 11:11-15.
52. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004; 55:319-331.